Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14314487 | 0.87 | LMNA (0.37) | LMNAMEN1KMT2AALDH1A1GRK6 | |
| SCHEMBL15233470 | 0.84 | LMNA (0.45) | LMNAKMT2AALDH1A1POLBGAA | |
| SCHEMBL12854855 | 0.80 | LMNA (0.38) | LMNAMEN1KMT2APOLBGAA | |
| SCHEMBL12851448 | 0.77 | ALDH1A1 (0.39) | LMNAMEN1KMT2AALDH1A1GAA | |
| SCHEMBL12854921 | 0.75 | LMNA (0.39) | LMNAKMT2AALDH1A1POLBGAA | |
| SCHEMBL18999673 | 0.71 | P2RX7 (0.39) | LMNAMEN1KMT2AALDH1A1GRK6 | |
| SCHEMBL235080 | 0.66 | KDM4E (0.65) | ALDH1A1POLB | |
| SCHEMBL8648555 | 0.64 | KDM4E (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL104455 | 0.64 | KDM4E (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11856358 | 0.63 | KDM4E (0.70) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322770-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-12-20 | — | — | US | disclosed |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322770-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | LMNA 700/4885MEN1 4101/4885KMT2A 3300/4885 |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | LMNA 700/4885MEN1 4101/4885KMT2A 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.